Patents Assigned to Genentech
  • Anti-HER2 antibody variants
    Patent number: 8840896
    Abstract: The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: September 23, 2014
    Assignee: Genentech, Inc.
    Inventors: Henry B. Lowman, Resi B. Gerstner, Paul J. Carter
  • ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS
    Publication number: 20140275032
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, X5, X6, Y, Z, G, R1a, R2a, R1b, R2b, R3, R4, R5 and R6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Genentech, Inc.
    Inventors: Benjamin Fauber, Olivier Rene, Monique Bodil van Niel, Stuart Ward
  • COMBINATIONS OF A MEK INHIBITOR COMPOUND WITH AN HER3/EGFR INHIBITOR COMPOUND AND METHODS OF USE
    Publication number: 20140271634
    Abstract: The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and a HER3/EGFR inhibitor (such as MEHD7945A). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicants: The Regents of the University of California, Genentech, Inc.
    Inventors: Mark X. Sliwkowski, Wolfgang Michael Korn
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE
    Publication number: 20140275106
    Abstract: The invention provides a combination of a) a compound of Formula Ia: [insert Formula Ia], or a pharmaceutically acceptable salt thereof, and b) vemurafenib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
    Type: Application
    Filed: March 30, 2012
    Publication date: September 18, 2014
    Applicant: GENENTECH, INC.
    Inventors: Klaus Hoeflich, Mark Merchant
  • ANTI-NOTCH NRR ANTIBODIES AND METHODS USING SAME
    Publication number: 20140271624
    Abstract: The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: February 11, 2014
    Publication date: September 18, 2014
    Applicant: Genentech, Inc.
    Inventors: Christian W. Siebel, Yan Wu
  • PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS
    Publication number: 20140275523
    Abstract: Processes are described for the preparation of PI3K inhibitor, GDC-0032, Formula I, having the structure: and intermediates useful for the preparation of I.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Genentech, Inc.
    Inventors: Remy Angelaud, Danial R. Beaudry, Diane E. Carrera, Sushant Malhotra, Travis Remarchuk, Frederic St-Jean
  • Humanized anti-beta7 antagonists and uses therefor
    Patent number: 8835133
    Abstract: The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: September 16, 2014
    Assignee: Genentech, Inc.
    Inventors: Sherman Fong, Mark S. Dennis
  • Inhibitors of IAP
    Patent number: 8835393
    Abstract: The invention provides novel compounds that are inhibitors of IAPs having the general formula: wherein X1, X2, X3, Y, A, R1, R2, R3, R4, R4?, R5, R5?, R6 and R6? are as described herein. The compouds of the invention may be used to induce apoptosis in cells (or sensitise cells to apoptosis) in which IAPs are overexpressed or otherwise implicated in resistance to normal apoptotic processes. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment cancers.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: September 16, 2014
    Assignee: Genentech, Inc.
    Inventors: Danette Dudley, John A. Flygare, Chudi Ndubaku
  • Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
    Patent number: 8835434
    Abstract: The present invention provides compounds, including pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: September 16, 2014
    Assignees: Array Biopharma, Inc., Genentech, Inc.
    Inventors: Josef R. Bencsik, James F. Blake, Nicholas C. Kallan, Ian S. Mitchell, Keith Lee Spencer, Dengming Xiao, Rui Xu, Christine Chabot, Steven Do, Jun Liang, Brian Safina, Birong Zhang
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ABIRATERONE, AND METHODS OF USE
    Publication number: 20140256691
    Abstract: The invention provides a combination of a) a compound of Formula (Ia): or a pharmaceutically acceptable salt thereof, and b) abiraterone or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
    Type: Application
    Filed: March 30, 2012
    Publication date: September 11, 2014
    Applicant: GENENTECH, INC.
    Inventors: Michelle Nannini, Deepak Sampath
  • N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use
    Patent number: 8828990
    Abstract: The present invention relates to compounds of Formula I: wherein R1, R2, R3, A1, A2, A3, A4, Y1 and Y2 and D have the meaning described herein. The present invention also relates to pharmaceutical compositions comprising such compounds and therapeutic uses thereof.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: September 9, 2014
    Assignee: Genentech, Inc.
    Inventors: Zhonghua Pei, Joseph P. Lyssikatos, Wendy Lee, Kirk D. Robarge
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
    Publication number: 20140248262
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: September 6, 2013
    Publication date: September 4, 2014
    Applicant: Genentech, Inc.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother
  • ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE
    Publication number: 20140248286
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 4, 2014
    Applicant: Genentech, Inc.
    Inventors: Min Xu, Mercedesz Balazs, Ning Chai, Nancy Chiang, Henry Chiu, Zhonghua Lin, Patrick Lupardus, Gerald R. Nakamura, Hyunjoo Park, Lee Swem
  • GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN EGFR ANTAGONIST CANCER THERAPY
    Publication number: 20140248609
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.
    Type: Application
    Filed: October 4, 2013
    Publication date: September 4, 2014
    Applicant: Genentech, Inc.
    Inventor: Robert D. Mass
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20140249127
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: February 14, 2014
    Publication date: September 4, 2014
    Applicants: Genentech, Inc., Array BioPharma Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • Azetidine derivatives
    Patent number: 8822505
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1 to R8 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: September 2, 2014
    Assignee: Genentech, Inc.
    Inventors: Lilli Anselm, David Banner, Wolfgang Haap, Bernd Kuhn, Thomas Luebbers, Jens-Uwe Peters, Beat Spinnler
  • Pyrazole aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 8815882
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: August 26, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Zachary Kevin Sweeney
  • Mediators of hedgehog signaling pathways, compositions and uses related hereto
    Patent number: 8815895
    Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: August 26, 2014
    Assignees: Curis, Inc., Genentech, Inc.
    Inventors: Oivin M. Guicherit, Edward Andrew Boyd, Shirley Ann Brunton, Stephen Price, John Harry Alexander Stibbard, Colin H. Mackinnon
  • Serine/threonine kinase inhibitors
    Patent number: 8815877
    Abstract: Compounds having the formula I wherein A, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, Ra, Rb, X1, X2, X3 and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: August 26, 2014
    Assignee: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, James Crawford, Wendy Lee, Simon Mathieu, Joachim Rudolph
  • INHIBITION OF TUMOR METASTASIS
    Publication number: 20140234312
    Abstract: The invention provides Nrp2 antagonists, such as anti-Nrp2 antibodies, and their use in the prevention and treatment of tumor metastasis.
    Type: Application
    Filed: June 11, 2013
    Publication date: August 21, 2014
    Applicant: GENENTECH, INC.
    Inventors: Yan Wu, Wei-Ching Liang, Ryan Jefferson Watts, Anil Durgadas